Martin D. Madaus's most recent trade in Repligen Corp. was a trade of 1,800 Common Stock done at an average price of $112.1 . Disclosure was reported to the exchange on Aug. 8, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Repligen Corp | Martin D. Madaus | Director | Purchase of securities on an exchange or from another person at price $ 112.13 per share. | 08 Aug 2025 | 1,800 | 1,800 (0%) | 0% | 112.1 | 201,830 | Common Stock |
| Repligen Corp | Martin D. Madaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 1,800 | 1,800 | - | - | Stock Option (Right to Buy) | |
| Repligen Corp | Martin D. Madaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 973 | 5,586 (0%) | 0% | 0 | Common Stock | |
| Hologic | Martin D. Madaus | Director | Purchase of securities on an exchange or from another person at price $ 55.24 per share. | 07 May 2025 | 5,445 | 5,445 (0%) | 0% | 55.2 | 300,760 | Common Stock |
| Hologic | Martin D. Madaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 5,535 | 5,535 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Hologic | Martin D. Madaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 1,864 | 2,206 (0%) | 0% | - | Common Stock | |
| Azenta Inc | Martin D. Madaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 4,040 | 4,040 | - | - | Restricted Stock Unit | |
| Quanterix Corp | Martin D. Madaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 15,821 | 15,821 | - | - | Stock Option (Right to Buy) | |
| Quanterix Corp | Martin D. Madaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 7,435 | 36,908 (0%) | 0% | 0 | Common Stock | |
| Hologic | Martin D. Madaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2024 | 342 | 342 (0%) | 0% | - | Common Stock | |
| Azenta Inc | Martin D. Madaus | Director | Purchase of securities on an exchange or from another person at price $ 40.77 per share. | 19 Nov 2024 | 4,940 | 7,405 (0%) | 0% | 40.8 | 201,404 | Common |
| Repligen Corp | Martin D. Madaus | Director | Purchase of securities on an exchange or from another person at price $ 124.54 per share. | 14 Jun 2024 | 915 | 3,913 (0%) | 0% | 124.5 | 113,954 | Common Stock |
| Repligen Corp | Martin D. Madaus | Director | Purchase of securities on an exchange or from another person at price $ 125.46 per share. | 14 Jun 2024 | 700 | 4,613 (0%) | 0% | 125.5 | 87,822 | Common Stock |
| Repligen Corp | Martin D. Madaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 1,376 | 1,376 | - | - | Stock Option (Right to Buy) | |
| Repligen Corp | Martin D. Madaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 701 | 2,998 (0%) | 0% | 0 | Common Stock | |
| Azenta Inc | D. Madaus Martin | Director | Grant, award, or other acquisition of securities at price $ 65.93 per share. | 12 Feb 2024 | 2,465 | 2,465 (0%) | 0% | 65.9 | 162,517 | Common |
| Quanterix Corp | Martin D. Madaus | Director | 02 Jan 2024 | 6,412 | 6,412 | - | - | Stock Option (Right to Buy) | ||
| Quanterix Corp | D. Martin Madaus | Director | 02 Jan 2024 | 2,947 | 29,473 (0%) | 0% | 0 | Common Stock | ||
| Repligen Corp | Martin D. Madaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 1,487 | 1,487 | - | - | Stock Option (Right to Buy) | |
| Repligen Corp | Martin D. Madaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 686 | 2,297 (0%) | 0% | 0 | Common Stock | |
| Repligen Corp | Martin D. Madaus | Director | Purchase of securities on an exchange or from another person at price $ 156.18 per share. | 24 Mar 2023 | 500 | 1,611 (0%) | 0% | 156.2 | 78,090 | Common Stock |
| Repligen Corp | Martin D. Madaus | Director | Purchase of securities on an exchange or from another person at price $ 159.19 per share. | 24 Mar 2023 | 500 | 1,111 (0%) | 0% | 159.2 | 79,595 | Common Stock |
| Repligen Corp | Martin D. Madaus | Director | Purchase of securities on an exchange or from another person at price $ 161.15 per share. | 24 Mar 2023 | 500 | 611 (0%) | 0% | 161.2 | 80,575 | Common Stock |
| Repligen Corp | Martin D. Madaus | Director | 24 Mar 2023 | 11 | 11 (0%) | 0% | 186.2 | 2,048 | Common Stock | |
| Standard BioTools Inc | Martin D. Madaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2023 | 29,665 | 76,161 (0%) | 0% | 0 | Common Stock | |
| Repligen Corp | Martin D. Madaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 1,819 | 1,819 | - | - | Stock Option (Right to Buy) | |
| Repligen Corp | Martin D. Madaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 239 | 239 | - | - | Stock Option (Right to Buy) | |
| Repligen Corp | Martin D. Madaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 111 | 111 (0%) | 0% | 0 | Common Stock | |
| Quanterix Corp | Martin D. Madaus | Director | 03 Jan 2023 | 12,124 | 12,124 | - | - | Stock Option (Right to Buy) | ||
| Quanterix Corp | Martin D. Madaus | Director | 03 Jan 2023 | 8,083 | 26,526 (0%) | 0% | 0 | Common Stock | ||
| Quanterix Corp | Martin D. Madaus | Director | 10 Aug 2022 | 89,667 | 254,633 (0%) | 0% | 8.4 | 755,543 | Common Stock | |
| Standard BioTools Inc | Martin D. Madaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 42,571 | 42,571 | - | - | Stock Option (Right to Buy) | |
| Standard BioTools Inc | Martin D. Madaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 30,914 | 46,766 (0%) | 0% | 0 | Common Stock | |
| Standard BioTools Inc | Martin D. Madaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2022 | 23,401 | 23,401 | - | - | Stock Option (Right to Buy) | |
| Standard BioTools Inc | Martin D. Madaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2022 | 15,852 | 15,852 (0%) | 0% | 0 | Common Stock | |
| Quanterix Corp | Martin D. Madaus | Director | 03 Jan 2022 | 4,002 | 4,002 | - | - | Stock Option (Right to Buy) | ||
| Quanterix Corp | Martin D. Madaus | Director | 03 Jan 2022 | 2,668 | 18,016 (0%) | 0% | 0 | Common Stock | ||
| Quanterix Corp | Martin D. Madaus | Director | 03 Jan 2022 | 427 | 18,443 (0%) | 0% | 42.4 | 18,109 | Common Stock | |
| Quanterix Corp | Martin D. Madaus | Director | 01 Oct 2021 | 354 | 15,348 (0%) | 0% | 51.2 | 18,118 | Common Stock | |
| Quanterix Corp | Martin D. Madaus | Director | 01 Jul 2021 | 304 | 14,994 (0%) | 0% | 59.5 | 18,082 | Common Stock | |
| Quanterix Corp | Martin D. Madaus | Director | 04 Jan 2021 | 7,900 | 7,900 | - | - | Stock Option (Right to Buy) | ||
| Quanterix Corp | Martin D. Madaus | Director | 04 Jan 2021 | 2,270 | 13,986 (0%) | 0% | 0 | Common Stock | ||
| Quanterix Corp | Martin D. Madaus | Director | 04 Jan 2021 | 410 | 14,396 (0%) | 0% | 44.1 | 18,085 | Common Stock |